International Journal of Advances in Science, Engineering and Technology(IJASEAT)
current issues
Volume-7, Issue-1, Spl. Iss-1  ( Feb, 2019 )
Statistics report
May
Submitted Papers : 80
Accepted Papers : 10
Rejected Papers : 70
Acc. Perc : 12%
  Journal Paper

Paper Title
The Effect of Lisdexamfetamine Dimesylate Augmentation Therapy in Adult Patients with Residual Symptoms of Major Depressive Disorder, with or without Adult ADHD

Abstract
Objective: Evaluate the Efficacy of Lisdexamfetamine Dimesylate (LDX) Augmentation for Treatment of MDD in Patients with or without Comorbid Attention Deficit Hyperactivity Disorder (ADHD). WHO reports that there are 322 million people suffering from depression worldwide. The symptoms of depression are associated with impairment of psycho socio occupational functioning. 60% of Major Depressive Disorder (MDD) patients do not achieve adequate response or remission with SSRI monotherapy. American Psychiatric Association (APA) recommends augmentation therapy with various medications such as mood stabilizers, antipsychotic medication, stimulants, anticonvulsants, etc. Atypical antipsychotics are beneficial, but adverse events such as metabolic effects are a concern. Studies have shown the efficacy of stimulants in treating patients with partial or poor responders who were treated with monotherapy of SSRI. Conclusion: Non-responders and partial responders of MDD patients with or without ADHD show considerable improvement in their psychosocial occupational functioning when LDX was added as an augmenter. Index Terms- Augmentation therapy, Cognition, Lisdexamfetamine Dimesylate, Major Depressive Disorder.


Author - Sunny Johnson, Muhammad Ali Alabedy, Danial Abidi, Ryan C Poolay

| PDF |
Viewed - 37
| Published on 2017-09-11
   
   
IRAJ Other Journals
IJASEAT updates
Volume-6,Issue-4, (Oct,2018)
The Conference World

JOURNAL SUPPORTED BY